Important note: Information in this article was accurate in July 2005. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 6, No. 7, July 2005
Simon Collins, HIV i-Base
Based on the results from Phase 2 studies, and supported by safety data in a rapidly enrolled group of 300 additional patients, Tibotec announced on 15 June that it plans to submit it’s new protease inhibitor (TMC114) for early approval. This is the first time in ten years (since indinavir) that Phase 2 data have been sufficiently impressive, in a population with currently unmet treatment needs, to justify accelerating approval even more quickly than current Fast Track system. TMC-114 has activity against a broad range of currently PI-resistant virus.
Importantly, an expanded access programme will start in the Autumn 2005, that will provide guaranteed access to TMC-114 for people in greatest need of life-saving treatment. This will be an international programme (initially 24,000 places worldwide) for heavily treatment-experienced adults, with CD4 count <100 cells/mm3. The planned phase 3 studies will continue to recruit and enroll patients with higher CD4 counts.
The results from the 24-week combined interim analysis of the phase IIB trials of TMC114 were presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI) in February this year and were covered in HTB April 2005. [1]
Patients in the highest dose group, 600mg/100mg BID, plus optimised background regimen, experienced a mean reduction in plasma HIV RNA of -1.85 log, compared to a reduction of -0.27 log in the control group. These studies will continue to 144 weeks.
Based on these 24-week results, the selected dose of TMC114/RTV for treatment-experienced patients in phase III trials is 600mg/100mg BID. TMC114 will be studied in both treatment-experienced and -naïve patients in phase III trials.
Source: Tibotec PR
Reference:
1. McKerrow G. 24-week efficacy of TMC114: dramatic early activity in heavily-experienced patients, HIV Treat Bull 2005 Apr 16(4);18; [Conf Retroviruses Opportunistic Infect. 2005 Feb 22-25;12th: Abstract No. 164LB.]
050710
IB050607-14
©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
